ArticleJournal of functional biomaterials2025
Evaluation of Composites Comprising Spherical, Porous, Sintered β-Tricalcium Phosphate Particles and Cyanoacrylate as Bone Cement.
Article in Journal of functional biomaterials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Bone cements based on polymethyl methacrylate (PMMA) remain the clinical standard for joint replacement and vertebral augmentation but suffer from several major challenges. These include excessive stiffness compared with cancellous bone, lack of resorption and osteoconductivity, and thermal necrosis during curing. Calcium phosphate cements (CPCs) are bioactive and resorbable but tend to exhibit low mechanical strength, poor injectability and brittle fracture. The work reported herein developed an injectable composite bone cement by combining spherical, porous, sintered β-tricalcium phosphate (β-TCP) particles with a cyanoacrylate adhesive. The β-TCP granules provided bioactivity and a favorable microarchitecture while the cyanoacrylate ensured strong adhesion and rapid setting. Ion substitution with Mg, Na and Si was found to modify the surface acidity of the material while also inhibiting cyanoacrylate polymerization, thereby extending the setting time and lowering the exotherm temperature. This composite exhibited high chemical stability, smooth injectability and early surface reactivity indicative of osteoconductivity. The compressive strength of the material stabilized at approximately 40 MPa and so exceeded that of cancellous bone. This new material also showed ductility, energy absorption and superior impact resistance, although its tensile and fatigue resistance remained limited. Importantly, the composite provided strength comparable to that of PMMA in cemented models during fixation tests and significantly outperformed CPCs in cementless tibial tray fixation experiments. These findings demonstrate that the present β-TCP/cyanoacrylate cement bridges the gap between PMMA and CPCs by combining injectability and mechanical reliability with bioactivity. This cement is therefore a promising next-generation option for minimally invasive osteoporotic fracture treatment and revision arthroplasty.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.